Therapeutic RSK1 Targeting in Myeloid Malignancies

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint removed 7 → 6 primary endpoints
See other at-risk trials from Washington University School of Medicine

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 18 → 30 participants Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Trial arms changed: 4 → 7
    • Eligibility criteria expanded, about 84 words
    • Secondary endpoints revised (7)
    • Site contact updated
    • Collaborators: 3 to 4
    • Study title expanded, about 1 word
  2. Recruitment opened
    • Start date changed from estimate of May 31, 2026 to May 20, 2026
    • Site details revised
    v3
  3. Start date: Mar 31, 2026 to May 31, 2026
    • Primary and study completion pushed from Oct 31, 2028 to Dec 31, 2028
    • Eligibility criteria expanded, about 77 words
    • Collaborators: 1 to 3
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study hypothesizes that PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), is safe and well tolerated in participants with myelofibrosis (MF) and myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPNs) and will improve spleen response, symptom response, and bone marrow histopathological response.
Trial Details
NCT Number NCT07379125
Lead Sponsor Washington University School of Medicine
Collaborators: Phoenix Molecular Designs, The Foundation for Barnes-Jewish Hospital, Swim Across America, Blood Cancer United
Conditions
(from sponsor)		 Myeloid Malignancy
Related terms Anemia, Bone Marrow Diseases, Bone Marrow Neoplasms, Hematologic Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Juvenile, Myeloproliferative Disorders, Primary Myelofibrosis, Splenomegaly, Thrombocytosis
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov